GO
Loading...

Enter multiple symbols separated by commas

Takeover Bids

More

  • Faber Report: Hillshire to acquire Pinnacle Monday, 12 May 2014 | 10:16 AM ET
    Faber Report: Hillshire to acquire Pinnacle

    CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.

  • What Cramer expects from IPO market Monday, 12 May 2014 | 9:08 AM ET
    What Cramer expects from IPO market

    Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.

  • Ackman: Makes sense to be partners with Icahn instead of enemies

    Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."

  • Ackman: Allergan, Valeant merger economically right thing to do

    Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.

  • Ackman: No alternative to Fannie and Freddie Monday, 5 May 2014 | 4:01 PM ET
    Ackman: No alternative to Fannie and Freddie

    CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.

  • AstraZeneca rejects new Pfizer bid Friday, 2 May 2014 | 9:07 AM ET
    AstraZeneca rejects new Pfizer bid

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Pfizer prepares sweeter bid for AstraZeneca Thursday, 1 May 2014 | 2:49 PM ET

    Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.

  • GE's Immelt: Alstom deal will be executed Wednesday, 30 Apr 2014 | 1:19 PM ET
    GE's Immelt: Alstom deal will be executed

    Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE's big bid for Alstom Wednesday, 30 Apr 2014 | 10:47 AM ET
    GE's big bid for Alstom

    Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE CEO confident Alstrom deal will go through Wednesday, 30 Apr 2014 | 9:36 AM ET
    GE CEO confident Alstrom deal will go through

    Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.

  • Alstom backs GE bid but Siemens sweetens deal Wednesday, 30 Apr 2014 | 7:02 AM ET
    Alstom backs GE bid but Siemens sweetens deal

    CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.

  • Alstrom bidding war standoff: GE vs. SI Wednesday, 30 Apr 2014 | 6:07 AM ET
    Alstrom bidding war standoff: GE vs. SI

    Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.

  • Siemens will make Alstom offer: Report Tuesday, 29 Apr 2014 | 11:11 AM ET
    Siemens will make Alstom offer: Report

    CNBC's David Faber reports Siemens will make an offer for Alstonm.

  • Pfizer engaging in legal tax avoidance: Bernstein Monday, 28 Apr 2014 | 3:21 PM ET
    Pfizer engaging in legal tax avoidance: Bernstein

    Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.

  • Pfizer, AstraZeneca about drug pipeline: Pro Monday, 28 Apr 2014 | 11:23 AM ET
    Pfizer, AstraZeneca about drug pipeline: Pro

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer pushes for $100 billion AstraZeneca deal Monday, 28 Apr 2014 | 10:10 AM ET
    Pfizer pushes for $100 billion AstraZeneca deal

    Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • AstraZeneca not a great company: Cramer Monday, 28 Apr 2014 | 9:01 AM ET
    AstraZeneca not a great company: Cramer

    The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.

  • Hedge fund & big pharma pair up Wednesday, 23 Apr 2014 | 1:32 PM ET
    Hedge fund & big pharma pair up

    CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.

  • Carl Icahn's take on Ackman & Valeant Wednesday, 23 Apr 2014 | 9:19 AM ET
    Carl Icahn's take on Ackman & Valeant

    Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

  • Cramer: Can't lose if you're Ackman Wednesday, 23 Apr 2014 | 9:17 AM ET
    Cramer: Can't lose if you're Ackman

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.